Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.

Détails

ID Serval
serval:BIB_2A17F8675253
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study.
Périodique
Blood
Auteur(s)
Jaccard A., Gachard N., Marin B., Rogez S., Audrain M., Suarez F., Tilly H., Morschhauser F., Thieblemont C., Ysebaert L., Devidas A., Petit B., de Leval L., Gaulard P., Feuillard J., Bordessoule D., Hermine O., GELA 
Collaborateur(s)
GOELAMS Intergroup
Contributeur(s)
GELA , Galicier L., Brice P., Golfier JB., Gisselbrecht C., Joly B., Fitoussi O., Coppo P., Corront B., Cumin I., Rossi JF., Coiteux V., Lenain P., Laurent G., Recher C., Hunault M., Milpied N., Bouabdallah K., Legay T., Girault S., Turlure P., Dmytruck N., Moreau S., Gourin MP., Touati M., Remenieras L.
ISSN
1528-0020 (Electronic)
ISSN-L
0006-4971
Statut éditorial
Publié
Date de publication
2011
Volume
117
Numéro
6
Pages
1834-1839
Langue
anglais
Notes
Publication types: Clinical Trial, Phase II ; Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Résumé
Extranodal NK/T-cell lymphoma, nasal type, is a rare and highly aggressive disease with a grim prognosis. No therapeutic strategy is currently identified in relapsing patients. We report the results of a French prospective phase II trial of an L-asparaginase-containing regimen in 19 patients with relapsed or refractory disease treated in 13 centers. Eleven patients were in relapse and 8 patients were refractory to their first line of treatment. L-Asparaginase-based treatment yielded objective responses in 14 of the 18 evaluable patients after 3 cycles. Eleven patients entered complete remission (61%), and only 4 of them relapsed. The median overall survival time was 1 year, with a median response duration of 12 months. The main adverse events were hepatitis, cytopenia, and allergy. The absence of antiasparaginase antibodies and the disappearance of Epstein-Barr virus serum DNA were significantly associated with a better outcome. These data confirm the excellent activity of L-asparaginase-containing regimens in extranodal NK/T-cell lymphoma. L-Asparaginase-based treatment should thus be considered for salvage therapy, especially in patients with disseminated disease. First-line L-asparaginase combination therapy for extranodal NK/T-cell lymphoma warrants evaluation in prospective trials. This trial is registered at www.clinicaltrials.gov as #NCT00283985.
Mots-clé
Aged, Antibodies/blood, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Asparaginase/administration & dosage, Asparaginase/immunology, DNA, Viral/blood, Dexamethasone/administration & dosage, Disease-Free Survival, Female, France, Herpesvirus 4, Human/isolation & purification, Humans, Kaplan-Meier Estimate, Lymphoma, Extranodal NK-T-Cell/drug therapy, Lymphoma, Extranodal NK-T-Cell/immunology, Male, Methotrexate/administration & dosage, Middle Aged, Prognosis, Prospective Studies, Recurrence, Remission Induction, Salvage Therapy
Pubmed
Web of science
Open Access
Oui
Création de la notice
15/03/2011 14:38
Dernière modification de la notice
20/08/2019 13:09
Données d'usage